Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Neuroepithelial

ClinicalTrials.gov lists 4,125 trials for Neoplasms, Neuroepithelial or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 284.

MeSH D018302 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,178 Phase 1/2 Phase 1/2 439 Phase 2 Phase 2 1,080 Phase 2/3 Phase 2/3 32 Phase 3 Phase 3 204 Phase 4 Phase 4 18 Not applicable Not applicable 521 Observational Observational 612 Phase 1 Phase 1 1,178 Phase 1/2 Phase 1/2 439 Phase 2 Phase 2 1,080 Phase 2/3 Phase 2/3 32 Phase 3 Phase 3 204 Phase 4 Phase 4 18 Not applicable Not applicable 521 Observational Observational 612

Trials per phase (log scale)

1 more section with rows

25 of the 4,125 trials are tagged with Neoplasms, Neuroepithelial itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasms, Neuroepithelial report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Neuroepithelial trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 20 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 208

1990: 4 trials (Not applicable 1, Phase 3 2, Phase 2 1) 1991: 4 trials (Observational 1, Phase 2 1, Phase 1 2) 1992: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 2) 1993: 6 trials (Observational 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 1994: 15 trials (Observational 1, Phase 3 3, Phase 2 7, Phase 1 4) 1995: 19 trials (Observational 3, Phase 3 2, Phase 2 9, Phase 1/2 1, Phase 1 4) 1996: 30 trials (Not applicable 1, Phase 3 1, Phase 2 19, Phase 1 9) 1997: 34 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 17, Phase 1/2 3, Phase 1 10) 1998: 48 trials (Observational 2, Not applicable 2, Phase 3 4, Phase 2/3 1, Phase 2 22, Phase 1/2 4, Phase 1 13) 1999: 50 trials (Observational 2, Phase 3 5, Phase 2 27, Phase 1/2 2, Phase 1 14) 2000: 57 trials (Observational 2, Phase 3 5, Phase 2 18, Phase 1/2 15, Phase 1 17) 2001: 67 trials (Observational 3, Not applicable 3, Phase 3 9, Phase 2 20, Phase 1/2 10, Phase 1 22) 2002: 66 trials (Observational 2, Not applicable 2, Phase 3 5, Phase 2 23, Phase 1/2 11, Phase 1 23) 2003: 60 trials (Observational 7, Not applicable 5, Phase 3 4, Phase 2 27, Phase 1/2 4, Phase 1 13) 2004: 78 trials (Observational 12, Not applicable 8, Phase 3 11, Phase 2 19, Phase 1/2 7, Phase 1 21) 2005: 113 trials (Observational 9, Not applicable 7, Phase 3 10, Phase 2 38, Phase 1/2 10, Phase 1 39) 2006: 109 trials (Observational 17, Not applicable 7, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 40, Phase 1/2 11, Phase 1 24) 2007: 123 trials (Observational 15, Not applicable 5, Phase 3 10, Phase 2/3 2, Phase 2 49, Phase 1/2 10, Phase 1 32) 2008: 132 trials (Observational 29, Not applicable 10, Phase 4 1, Phase 3 9, Phase 2 47, Phase 1/2 9, Phase 1 27) 2009: 141 trials (Observational 16, Not applicable 9, Phase 4 1, Phase 3 8, Phase 2 46, Phase 1/2 19, Phase 1 42) 2010: 148 trials (Observational 17, Not applicable 9, Phase 3 7, Phase 2 51, Phase 1/2 18, Phase 1 46) 2011: 144 trials (Observational 20, Not applicable 14, Phase 3 6, Phase 2/3 2, Phase 2 42, Phase 1/2 18, Phase 1 42) 2012: 121 trials (Observational 20, Not applicable 16, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 27, Phase 1/2 17, Phase 1 35) 2013: 135 trials (Observational 15, Not applicable 21, Phase 3 6, Phase 2 38, Phase 1/2 13, Phase 1 42) 2014: 151 trials (Observational 23, Not applicable 21, Phase 3 4, Phase 2/3 3, Phase 2 34, Phase 1/2 15, Phase 1 51) 2015: 149 trials (Observational 23, Not applicable 20, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 37, Phase 1/2 18, Phase 1 44) 2016: 167 trials (Observational 34, Not applicable 16, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 35, Phase 1/2 20, Phase 1 56) 2017: 169 trials (Observational 28, Not applicable 27, Phase 3 4, Phase 2/3 1, Phase 2 50, Phase 1/2 16, Phase 1 43) 2018: 189 trials (Observational 37, Not applicable 31, Phase 4 2, Phase 3 8, Phase 2/3 5, Phase 2 26, Phase 1/2 22, Phase 1 58) 2019: 153 trials (Observational 25, Not applicable 22, Phase 4 2, Phase 3 2, Phase 2/3 2, Phase 2 39, Phase 1/2 15, Phase 1 46) 2020: 173 trials (Observational 24, Not applicable 31, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 41, Phase 1/2 19, Phase 1 50) 2021: 168 trials (Observational 28, Not applicable 30, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 21, Phase 1 50) 2022: 208 trials (Observational 44, Not applicable 41, Phase 4 2, Phase 3 6, Phase 2 37, Phase 1/2 22, Phase 1 56) 2023: 184 trials (Observational 42, Not applicable 36, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 23, Phase 1/2 18, Phase 1 57) 2024: 207 trials (Observational 46, Not applicable 38, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 45, Phase 1/2 18, Phase 1 50) 2025: 198 trials (Observational 33, Not applicable 39, Phase 4 1, Phase 3 11, Phase 2/3 1, Phase 2 31, Phase 1/2 18, Phase 1 64)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 211
2025 198
2024 207
2023 184
2022 208
2021 168
2020 173
2019 153
2018 189
2017 169

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 535 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 2,374 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Neuroepithelial trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,178
Phase 1/2 439
Phase 2 1,080
Phase 2/3 32
Phase 3 204
Phase 4 18
Not applicable 521
Observational 612
Expanded access 41

How many Neoplasms, Neuroepithelial trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 171
Recruiting 651
Enrolling by invitation 18
Active, not recruiting 296
Available 14

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Neuroepithelial trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 284
Children's Oncology Group 105
Novartis Pharmaceuticals 38
European Organisation for Research and Treatment of Cancer - EORTC 32

Which drugs are being tested for Neoplasms, Neuroepithelial? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 160
Irinotecan 83
TOPOTECAN 68
Melphalan 65

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 487
Radiation Therapy 227
Bevacizumab 1 163
or carboplatin 125
Etoposid 122

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Neuroepithelial trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 1,130 260
Platelet count decreased 690 100
Vomiting 521 202
Headache 498 192
Neutrophil count decreased 487 76

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Neuroepithelial? (5)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro-oncology 2011 Yes
Intraoperative localization of subcortical brain lesions. Acta neurochirurgica 2008 Yes
Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathology and applied neurobiology 2001 Yes
EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity. Brain pathology (Zurich, Switzerland) 2019 No
Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain : a journal of neurology 2002 No

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages